Prof. Albiges shares LITESPARK-005 study results: Belzutifan improves PFS in pretreated mRCC patients

EAU Podcasts - A podcast by European Association of Urology - Sundays

Try Bookbeat 60! days for free, click here

Try Bookbeat 60! days for free, click here

Enjoy a whole world of audiobooks and e-books, everything from new releases to the classics

 Sponsored

Categories:

Education

In this podcast, UROONCO RCC associate editor Dr. Teele Kuusk (GB) talks with medical oncologist Prof. Laurence Albiges (FR), Head of the Department of Oncology at Gustave Roussy, about her abstract: Belzutifan versus everolimus in participants with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomised open-label phase III LITESPARK-005 study.Prof. Albiges discusses the study results she presented at ESMO 2023. LITESPARK-005 established HIF-2a inhibition as a novel t...